Human placental lactogen

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Jump to: navigation, search
chorionic somatomammotropin hormone 1 (placental lactogen)
Identifiers
Symbol CSH1
Entrez 1442
HUGO 2440
OMIM 150200
RefSeq NM_001317
UniProt Q6PF11
Other data
Locus Chr. 17 q22-q24
chorionic somatomammotropin hormone 2
Identifiers
Symbol CSH2
Entrez 1443
HUGO 2441
OMIM 118820
RefSeq NM_020991
UniProt P01243
Other data
Locus Chr. 17 q22-q24

WikiDoc Resources for

Human placental lactogen

Articles

Most recent articles on Human placental lactogen

Most cited articles on Human placental lactogen

Review articles on Human placental lactogen

Articles on Human placental lactogen in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Human placental lactogen

Images of Human placental lactogen

Photos of Human placental lactogen

Podcasts & MP3s on Human placental lactogen

Videos on Human placental lactogen

Evidence Based Medicine

Cochrane Collaboration on Human placental lactogen

Bandolier on Human placental lactogen

TRIP on Human placental lactogen

Clinical Trials

Ongoing Trials on Human placental lactogen at Clinical Trials.gov

Trial results on Human placental lactogen

Clinical Trials on Human placental lactogen at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Human placental lactogen

NICE Guidance on Human placental lactogen

NHS PRODIGY Guidance

FDA on Human placental lactogen

CDC on Human placental lactogen

Books

Books on Human placental lactogen

News

Human placental lactogen in the news

Be alerted to news on Human placental lactogen

News trends on Human placental lactogen

Commentary

Blogs on Human placental lactogen

Definitions

Definitions of Human placental lactogen

Patient Resources / Community

Patient resources on Human placental lactogen

Discussion groups on Human placental lactogen

Patient Handouts on Human placental lactogen

Directions to Hospitals Treating Human placental lactogen

Risk calculators and risk factors for Human placental lactogen

Healthcare Provider Resources

Symptoms of Human placental lactogen

Causes & Risk Factors for Human placental lactogen

Diagnostic studies for Human placental lactogen

Treatment of Human placental lactogen

Continuing Medical Education (CME)

CME Programs on Human placental lactogen

International

Human placental lactogen en Espanol

Human placental lactogen en Francais

Businness

Human placental lactogen in the Marketplace

Patents on Human placental lactogen

Experimental / Informatics

List of terms related to Human placental lactogen

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Phone:617-525-6884

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [2] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.


Human placental lactogen (HPL), also called human chorionic somatomammotropin, is a polypeptide placental hormone. Its structure and function is similar to that of human growth hormone. It modifies the metabolic state of the mother during pregnancy to facilitate the energy supply of the fetus. HPL is an anti-insulin.

Structure

HPL consists of 190 amino acids that are linked by two disulfite bonds and is secreted by the syncytiotrophoblast during pregnancy. Its molecular weight is 22,125. Like human growth hormone HPL is encoded by genes on chromosome 17q22-24. Its biologic half-life is 15 minutes.

Levels

HPL is only present during pregnancy with maternal serum levels rising in relation to the growth of the fetus and placenta. Maximum levels are reached near term, typically to 5–7 mg/ml. Higher levels are noted in patients with multiple gestation. Little HPL enters the fetal circulation.

Function

In a bioassay HPL mimics the action of prolactin, yet it is unclear if HPL has any role in human lactation.

HPL affects the metabolic system of the maternal organism. HPL increases production of insulin and IGF-1 and increases insulin resistance and carbohydrate intolerance. Chronic hypoglycemia leads to a rise in HPL. HPL induces lipolysis with the release of free fatty acids, increase in insulin secretion and insulin resistance. With fasting and release of HPL, free fatty acids become available for the maternal organism as fuel, so that relatively more glucose can be utilized by the fetus. Also, ketones formed from free fatty acids can cross the placenta and be used by the fetus. These events support energy supply to the fetus in states of starvation.

Clinical measurement of HPL

While HPL has been used as an indicator of fetal well-being and growth, other fetal monitoring methods have been found to be more reliable. Also, normal pregnancies have been reported with undetectable maternal levels of HPL.

References

  • Speroff L, Glass RH, Kase NG. Clinical Gynecologic Endocrinology and Infertility. Sixth edition. Lippincott Williams & Wilkins, Baltimore, MD 1999. ISNB 0-683-30379-1.

External links

WikiDoc Help Menu

Quick Start..

Editing basics

Advanced editing

Communicating your edits

Help Videos You Can Watch


Acknowledgement and Attribution Regarding Sources of Content

Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .

de:Humanes Plazentalaktogen

Personal tools